Pemvidutide PEMV

An experimental injectable weight-loss and liver-health drug in human trials for obesity and a serious form of fatty liver disease. Trial results show meaningful weight loss and improved liver health, though it remains unapproved while trials continue.

Also known as ALT-801

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial dosing under evaluation

Reported range Phase II trials: 1.2-2.4 mg once weekly

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of several months

Investigational GLP-1/glucagon dual agonist (Altimmune) for obesity and MASH; not an approved product.

Where this comes from Published Phase II clinical trial data (Altimmune)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.